Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2970006 | The Journal of Heart and Lung Transplantation | 2015 | 19 Pages |
Abstract
The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sofya MD, Jonathan P. MD, MS, Megan S. MD, Glen P. MBBS, PhD, John-David MD, Michael MD, Gregory I. MBBS, MD, Joyce S. MD, MAS, Hilary J. MD, Jasleen MD, MPH, Jeffrey A. MD, Lorriana E. MD, Christine K. MD, PhD, Steven R. MD,